AU2005251982B2 - 2H or 3H-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof - Google Patents

2H or 3H-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof Download PDF

Info

Publication number
AU2005251982B2
AU2005251982B2 AU2005251982A AU2005251982A AU2005251982B2 AU 2005251982 B2 AU2005251982 B2 AU 2005251982B2 AU 2005251982 A AU2005251982 A AU 2005251982A AU 2005251982 A AU2005251982 A AU 2005251982A AU 2005251982 B2 AU2005251982 B2 AU 2005251982B2
Authority
AU
Australia
Prior art keywords
alkyl
group
groups
compound
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005251982A
Other languages
English (en)
Other versions
AU2005251982A1 (en
Inventor
Laurent Dubois
Yannick Evanno
Christian Maloizel
Mireille Sevrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of AU2005251982A1 publication Critical patent/AU2005251982A1/en
Application granted granted Critical
Publication of AU2005251982B2 publication Critical patent/AU2005251982B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
AU2005251982A 2004-05-11 2005-05-10 2H or 3H-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof Ceased AU2005251982B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0405055 2004-05-11
FR0405055A FR2870239B1 (fr) 2004-05-11 2004-05-11 Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
PCT/FR2005/001154 WO2005121099A1 (fr) 2004-05-11 2005-05-10 Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
AU2005251982A1 AU2005251982A1 (en) 2005-12-22
AU2005251982B2 true AU2005251982B2 (en) 2011-04-28

Family

ID=34947852

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005251982A Ceased AU2005251982B2 (en) 2004-05-11 2005-05-10 2H or 3H-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof

Country Status (32)

Country Link
US (3) US7501449B2 (enExample)
EP (1) EP1747201B8 (enExample)
JP (1) JP4909889B2 (enExample)
KR (1) KR101165483B1 (enExample)
CN (1) CN100577648C (enExample)
AR (1) AR049090A1 (enExample)
AT (1) ATE411295T1 (enExample)
AU (1) AU2005251982B2 (enExample)
BR (1) BRPI0508563A (enExample)
CA (1) CA2557942C (enExample)
CR (1) CR8570A (enExample)
CY (1) CY1108710T1 (enExample)
DE (1) DE602005010418D1 (enExample)
DK (1) DK1747201T3 (enExample)
EC (1) ECSP066810A (enExample)
ES (1) ES2315898T3 (enExample)
FR (1) FR2870239B1 (enExample)
HR (1) HRP20090012T3 (enExample)
IL (1) IL177632A (enExample)
MA (1) MA28372A1 (enExample)
NO (1) NO20064073L (enExample)
NZ (1) NZ549330A (enExample)
PL (1) PL1747201T3 (enExample)
PT (1) PT1747201E (enExample)
RS (1) RS50724B (enExample)
RU (1) RU2379293C2 (enExample)
SI (1) SI1747201T1 (enExample)
TN (1) TNSN06258A1 (enExample)
TW (1) TWI349004B (enExample)
UA (1) UA85866C2 (enExample)
WO (1) WO2005121099A1 (enExample)
ZA (1) ZA200607244B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2870239B1 (fr) * 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
WO2007088528A1 (en) * 2006-02-03 2007-08-09 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Microtubule targeting agents
CL2008000793A1 (es) * 2007-03-23 2008-05-30 Xenon Pharmaceuticals Inc Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.
MX2016000669A (es) * 2013-07-15 2016-11-11 Basf Se Compuestos plaguicidas.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0607076A1 (fr) * 1993-01-15 1994-07-20 Synthelabo Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA
TW403738B (en) * 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
FR2741073B1 (fr) * 1995-11-09 1997-12-12 Synthelabo Derives de 4,5-dihydroimidazo(1,2-a)pyrrolo(1,2,3-cd) benzimidazole, leur preparation et leur application en therapeutique
ID16283A (id) * 1996-03-20 1997-09-18 Astra Pharma Prod Senyawa yang berguna dibidang farmasi
ZA9810490B (en) * 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
MXPA03001945A (es) * 2000-09-06 2003-09-10 Neurogen Corp Tetrahidroindazoles sustituidos con arilo y su uso como ligandos para el receptor gaba-a.
ATE425148T1 (de) * 2000-09-18 2009-03-15 Eisai R&D Man Co Ltd Triazinone sowie deren medizinale anwendung
FR2870239B1 (fr) * 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
EP1747201A1 (fr) 2007-01-31
AR049090A1 (es) 2006-06-28
UA85866C2 (uk) 2009-03-10
DK1747201T3 (da) 2009-02-16
EP1747201B1 (fr) 2008-10-15
TWI349004B (en) 2011-09-21
ES2315898T3 (es) 2009-04-01
JP2007537212A (ja) 2007-12-20
AU2005251982A1 (en) 2005-12-22
IL177632A (en) 2012-07-31
WO2005121099A1 (fr) 2005-12-22
PT1747201E (pt) 2009-01-19
US8114899B2 (en) 2012-02-14
US7501449B2 (en) 2009-03-10
US20090143380A1 (en) 2009-06-04
CY1108710T1 (el) 2014-04-09
ATE411295T1 (de) 2008-10-15
US20070105932A1 (en) 2007-05-10
US20120108584A1 (en) 2012-05-03
HRP20090012T3 (en) 2009-02-28
MA28372A1 (fr) 2006-12-01
IL177632A0 (en) 2006-12-31
PL1747201T3 (pl) 2009-04-30
KR20070007796A (ko) 2007-01-16
FR2870239A1 (fr) 2005-11-18
DE602005010418D1 (de) 2008-11-27
FR2870239B1 (fr) 2006-06-16
RU2379293C2 (ru) 2010-01-20
NO20064073L (no) 2006-11-06
CN100577648C (zh) 2010-01-06
ZA200607244B (en) 2008-04-30
CA2557942A1 (fr) 2005-12-22
NZ549330A (en) 2010-08-27
RS50724B (sr) 2010-08-31
US8258168B2 (en) 2012-09-04
CA2557942C (fr) 2013-08-06
CN1930131A (zh) 2007-03-14
TW200604181A (en) 2006-02-01
JP4909889B2 (ja) 2012-04-04
BRPI0508563A (pt) 2007-08-14
RU2006132325A (ru) 2008-03-20
TNSN06258A1 (fr) 2007-12-03
ECSP066810A (es) 2006-11-16
EP1747201B8 (fr) 2009-02-18
CR8570A (es) 2007-10-04
HK1104288A1 (en) 2008-01-11
KR101165483B1 (ko) 2012-07-13
SI1747201T1 (sl) 2009-04-30

Similar Documents

Publication Publication Date Title
CN109111426B (zh) 一类稠合双环杂芳基或芳基化合物，及其用途
CN118005656A (zh) Kras g12c突变蛋白嘧啶并噻喃二酮类抑制剂的制备及其应用
US8258168B2 (en) 2H or 3H-benzo[E]indazol-1-YL carbamate derivatives, the preparation and therapeutic use thereof
JP5277208B2 (ja) ３−ヘテロアリール−３，５−ジヒドロ−４−オキソ−４Ｈ−ピリダジノ［４，５−ｂ］インドール−１−アセトアミド誘導体、それらの製造、および治療におけるそれらの適用
EA006251B1 (ru) ПРОИЗВОДНЫЕ 3-ГЕТЕРОАРИЛ-3,5-ДИГИДРО-4-ОКСО-4H-ПИРИДАЗИНО[4,5-b]ИНДОЛ-1-КАРБОКСАМИДА, ИХ ПОЛУЧЕНИЕ И ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
MXPA06009859A (en) 2h or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof
HK1104288B (en) 2h or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof
WO2025237398A1 (zh) 五元杂芳环衍生物及其用途
CN116239594A (zh) 6-(咪唑并[1,2-a]吡啶-6-基)喹唑啉衍生物及用途
TW201043630A (en) Purine derivatives and anticancer agent using the same
HK1074632B (en) 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
HK1102371B (en) Intermediate compound of 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired